

Manuscript Number: COLSUB-D-18-00627R1

Title: Monoolein liquid crystalline phases for topical delivery of
crocetin

Article Type: Full Length Article

Keywords: crocetin, monoolein, polarized light microscopy, small angle x-
ray scattering, diffusion, tape-stripping

Corresponding Author: Dr. Elisabetta Esposito, Ph.D.

Corresponding Author's Institution: University of Ferrara

First Author: Elisabetta Esposito, Ph.D.

Order of Authors: Elisabetta Esposito, Ph.D.; Federica Carducci; Paolo
Mariani; Nicolas Huang; Fanny Simelière; Rita Cortesi; Giuseppe Romeo;
Carmelo Puglia

Manuscript Region of Origin: ITALY

Abstract: The present investigation concerns the production and
characterization of monoolein-water systems designed for cutaneous
administration of crocetin. The different monoolein crystalline phases
forming in the presence of crocetin as a function of added water have
been investigated by x-ray and polarized light microscopy. Franz cell was
employed to compare in vitro the crocetin diffusion from selected
monoolein water systems containing 95, 90 or 75 % w/w of monoolein, while
to investigate the performance of monoolein-water as transdermal delivery
systems, in vivo studies, based on tape stripping were performed. The
presence of micellar, lamellar and Q230 phases was found in the case of
systems containing monoolein 95, 90 and 75% w/w respectively, with a
viscosity almost directly proportional to the amount of added water. The
higher the amount of water, the longer the crocetin stability, while its
diffusion was slower in the case of more viscous systems. Tape stripping
results indicated a more rapid depletion of crocetin on stratum corneum
in the case of systems characterized by cubic phases, followed by
micellar and lamellar ones. This behaviour could be related to a more
rapid drug penetration throughout the deeper skin strata.

Response to Reviewers: Dr. Xinyuan Zhu, Ph.D
Editor

Colloids and Surfaces B: Biointerfaces

Dear Dr. Xinyuan Zhu, thank you for the refereeing of the manuscript
COLSUB-D-18-00627, "Monoolein liquid crystalline phases for topical
delivery of crocetin" by F. Carducci, P. Mariani, N. Huang, F. Simelière,
R. Cortesi, G. Romeo, C. Puglia and myself. We emended our manuscript
accordingly to the comments raised by the Reviewers. The corrections are
evidenced in yellow.

Detailed list of the changes made:

Reviewer #1

The manuscript describes the preparation and characterization of monoolein-water systems designed for cutaneous administration of crocetin. Formulations were obtained with different amounts of water (5-25%, w/w) and 0.02% (w/v) of crocetin. They were characterized by x-ray, polarized light microscopy, continuous flow rheometry, drug content, prediction of long term stability, in vitro diffusion and in vivo tape stripping experiments. Systems containing 75, 90 and 95% of monoolein showed to be suitable as platforms for crocetin delivery, but more in vivo studies should be performed. The work has been conducted and shows important results. However, some corrections are necessary.

1 - Graphical abstract should be improved, showing with more information about the in vitro and in vivo experiments (diffusion and tape stripping) Graphical abstract has been improved as suggested.

2 - Abstract has no space and what is "p/p"?

Space has been deleted from abstract. Moreover, the refuse term p/p (the Italian acronym of w/w) is now amended.

3 - In line 71, *Crocus sativus* should be correctly written (italic)

The name *Crocus sativus* has been corrected and written in italic

4 - Line 99, Is data in brief or supplementary material?

The sentence has been corrected indicating that "the protocol is reported in the supplementary materials section".

5 - Lines 110 - 118, is x-ray scattering or SAXS? Explain better

As rightly wondered by Reviewer #1, SAXS experiments were performed, thus as requested we specified this type of analyses at the beginning of paragraph (line 111).

6 - Lines 129-136, what is the gap between the cone and plate? Was the down curve performed?

The truncation gap of the cone-plate is 28 μm . This detail has been included in paragraph 2.6, lines 131-132. The down curves have been performed on M-80, M-90, M-95 and M-100 samples. The samples are all weakly thixotropic and slightly more thixotropic for M-90 at low shear rates. The new results are now included in par. 3.6 (lines 376-379) while in supplementary materials the methods and the curves (new Fig. S2) have been reported.

7 - Lines 158, Explain better. Protected from light? Line 183, what is "simple receptor phase"?

Line 158, now 152. CRT samples were put in amber glass vials to avoid CRT photodegradation.

Line 183, now 195. The word "simple" was replaced with the word "fresh".

8 - Lines 251-253, Was the CRT content 98% for all systems? Is this value the mean for all systems?

For all the tested monoolein-water systems the CRT content evaluated after disaggregation process and HPLC analyses was $98\% \pm 0.2$, with respect to the weight of CRT added to the monoolein-water mixture.

9 - Fig. 1 and Fig. 2 are changed in the text (lines 256-290)

The citation through the text of Figures 1 and 2 is now correct.

10 - Line 312, the method for spreadability should be explained in the text (not in supplementary material)

As suggested by Reviewer #1 the method for spreadability test was explained in the materials and Methods section of the manuscript.

11 - Lines 367-371, explain better. M-95 and M-85-CRT are micellar! What about formulations containing 15%?

M-85-CRT is not micellar, but cubic Ia3D (Q230), as reported in Table 2 and schematized in Figure S1. As reported in the text, (lines 296-298), In the case of M-85-CRT (Fig. 1A), birefringent anisotropic textures can be appreciated, probably because of the presence of phase coexistence. To accomplish with reviewer suggestion, the following phrase has been inserted: "anisotropic textures in the case of M-85-CRT" (lines 370-371).

12 - References are up to date and accordingly.

Reviewer #2

The manuscript entitled "Monoolein liquid crystalline phases for topical delivery of Crocetin" by Esposito et al. intends to develop and characterize different monoolein water systems for crocetin release. In my opinion, the manuscript is not complete to be published on Colloids and Surfaces B: Biointerfaces. More assays should be performed to be of interesting for the journal.

Also, the English need to be revised.

English language has been revised.

1 - Please provide the HPLC validation parameters.

Probably Reviewer #2 missed the information during the reading since HPLC validation parameters, namely linearity ($R^2 = 0.994$), repeatability (relative standard deviation 0.02%, $n = 6$ injections) and LOQ (0.03 $\mu\text{g/ml}$), are already present at the end of paragraph 2.8 CRT content (lines 162-164).

2 - Which membrane was used for the in vitro diffusion experiments?

As indicated in the Materials and Methods section par. 2.10 (line 185), for in vitro study a nylon membrane (Merck Millipore, 0.45 μm pore size) was used.

3 - Why the authors selected 8 h as the maximum for the diffusion experiments?

We thank the reviewer for this insightful observation. The experiments were conducted for 24 h, but only the linear portions of the curves were plotted, to evaluate the flux corresponding to the steady state. The following phrases have been inserted in the latest version of the manuscript: "At predetermined time intervals comprised between 0 and 24 h" (lines 192-193). "Fig 4 shows the diffusion kinetics corresponding to the linear part of the profile (from 0 to 8 h)," (lines 352-353).

4 - Why Figure 2 appears first on the text than Figure 1?

See point 9 Reviewer#1 for answer.

5 - Normally, the accelerated stability studies are conducted during 3 months at 40°C. Why the authors selected 25°C? Did the authors controlled the humidity?

We thank the reviewer for this observation, there was a mistake, the stability studies were conducted at 40°C. The humidity grade was comprised between 70-75% RH. This missed information is now included in the manuscript.

6 - Point 4 should be discussion and conclusion
As suggested by Reviewer #2, point 4 was changed accordingly.

Hoping that now the manuscript could be suitable for publication, I send
my best regards

Dr. Elisabetta Esposito

Dear. Prof. John L. Brash,

Enclosed please find the manuscript "Monoolein liquid crystalline phases for topical delivery of crocetin" by

Elisabetta Esposito*, Federica Carducci, Paolo Mariani, Nicolas Huang, Fanny Simelière, Rita Cortesi*, Giuseppe Romeo and Carmelo Puglia

The paper is submitted for possible publication on "Colloids and Surfaces B".

We believe that the reported results give an interesting contribution to the field of colloids characterization and technology.

The mesophases resulting in monoolein/water systems are fascinating but currently under-exploited for biological application. We have thoroughly characterized them by small angle x-ray scattering, polarized light microscopy and rheological analyses.

In addition, crocetin is a natural antioxidant molecule with several biological applications but very difficult to be solubilized in well tolerated biocompatible vehicles.

In vivo tape-stripping demonstrated the possibility to apply crocetin on the skin and to differently control its uptake using different monoolein concentrations.

For these reasons we think that publication of our findings can give valuable inputs to Colloids and Surfaces B readers.

Statistical summary

total number of words (excluding figure captions) 5995; Tables: 3, Figures: 5.

The manuscript is original, unpublished, it is not under consideration for publication elsewhere, and all authors have read and approved the text and consent to its publication.

I thank you in advance for consideration.

Best regards

Dr. Elisabetta Esposito

Ferrara, 11 april 2018

Dr. Xinyuan Zhu, Ph.D

Editor

Colloids and Surfaces B: Biointerfaces

Dear Dr. Xinyuan Zhu, thank you for the refereeing of the manuscript COLSUB-D-18-00627, "Monoolein liquid crystalline phases for topical delivery of crocetin" by F. Carducci, P. Mariani, N. Huang, F. Simelière, R. Cortesi, G. Romeo, C. Puglia and myself. We emended our manuscript accordingly to the comments raised by the Reviewers. The corrections are evidenced in yellow.

Detailed list of the changes made:

Reviewer #1

The manuscript describes the preparation and characterization of monoolein-water systems designed for cutaneous administration of crocetin. Formulations were obtained with different amounts of water (5-25%, w/w) and 0.02% (w/v) of crocetin. They were characterized by x-ray, polarized light microscopy, continuous flow rheometry, drug content, prediction of long term stability, in vitro diffusion and in vivo tape stripping experiments. Systems containing 75, 90 and 95% of monoolein showed to be suitable as platforms for crocetin delivery, but more in vivo studies should be performed. The work has been conducted and shows important results. However, some corrections are necessary.

1 - Graphical abstract should be improved, showing with more information about the in vitro and in vivo experiments (diffusion and tape stripping)

Graphical abstract has been improved as suggested.

2 - Abstract has no space and what is "p/p"?

Space has been deleted from abstract. Moreover, the refuse term p/p (the Italian acronym of w/w) is now amended.

3 - In line 71, Crocus sativus should be correctly written (italic)

The name *Crocus sativus* has been corrected and written in italic

4 - Line 99, Is data in brief or supplementary material?

The sentence has been corrected indicating that "the protocol is reported in the supplementary materials section".

5 - Lines 110 - 118, is x-ray scattering or SAXS? Explain better

As rightly wondered by Reviewer #1, SAXS experiments were performed, thus as requested we specified this type of analyses at the beginning of paragraph (line 111).

6 - Lines 129-136, what is the gap between the cone and plate? Was the down curve performed?

The truncation gap of the cone-plate is 28 μm . This detail has been included in paragraph 2.6, lines 131-132. The down curves have been performed on M-80, M-90, M-95 and M-100 samples. The samples are all weakly thixotropic and slightly more thixotropic for M-90 at low shear rates. The new results are now included in par. 3.6 (lines 376-379) while in supplementary materials the methods and the curves (new Fig. S2) have been reported.

7 - Lines 158, Explain better. Protected from light? Line 183, what is "simple receptor phase"?

Line 158, now 152. CRT samples were put in amber glass vials to avoid CRT photodegradation.

Line 183, now 195. The word "simple" was replaced with the word "fresh".

8 - Lines 251-253, Was the CRT content 98% for all systems? Is this value the mean for all systems?

For all the tested monoolein-water systems the CRT content evaluated after disaggregation process and HPLC analyses was 98 % \pm 0.2, with respect to the weight of CRT added to the monoolein-water mixture.

9 - Fig. 1 and Fig. 2 are changed in the text (lines 256-290)

The citation through the text of Figures 1 and 2 is now correct.

10 - Line 312, the method for spreadability should be explained in the text (not in supplementary material)

As suggested by Reviewer #1 the method for spreadability test was explained in the materials and Methods section of the manuscript.

11 - Lines 367-371, explain better. M-95 and M-85-CRT are micellar! What about formulations containing 15%?

M-85-CRT is not micellar, but cubic Ia3D (Q230), as reported in Table 2 and schematized in Figure S1. As reported in the text, (lines 296-298), In the case of M-85-CRT (Fig. 1A), birefringent anisotropic textures can be appreciated, probably because of the presence of phase coexistence.

To accomplish with reviewer suggestion, the following phrase has been inserted: "anisotropic textures in the case of M-85-CRT" (lines 370-371).

12 - References are up to date and accordingly.

Reviewer #2

The manuscript entitled "Monoolein liquid crystalline phases for topical delivery of Crocetin" by Esposito et al. intends to develop and characterize different monoolein water systems for crocetin release. In my opinion, the manuscript is not complete to be published on Colloids and Surfaces B: Biointerfaces. More assays should be performed to be of interesting for the journal.

Also, the English need to be revised.

English language has been revised.

1 - Please provide the HPLC validation parameters.

Probably Reviewer #2 missed the information during the reading since HPLC validation parameters, namely linearity ($R^2 = 0.994$), repeatability (relative standard deviation 0.02%, $n = 6$ injections) and LOQ (0.03 $\mu\text{g/ml}$), are already present at the end of paragraph 2.8 CRT content (lines 162-164).

2 - Which membrane was used for the in vitro diffusion experiments?

As indicated in the Materials and Methods section par. 2.10 (line 185), for in vitro study a nylon membrane (Merck Millipore, 0.45 μm pore size) was used.

3 - Why the authors selected 8 h as the maximum for the diffusion experiments?

We thank the reviewer for this insightful observation. The experiments were conducted for 24 h, but only the linear portions of the curves were plotted, to evaluate the flux corresponding to the steady state. The following phrases have been inserted in the latest version of the manuscript: "At predetermined time intervals comprised between 0 and 24 h" (lines 192-193). "Fig 4 shows the diffusion kinetics corresponding to the linear part of the profile (from 0 to 8 h)," (lines 352-353).

4 - Why Figure 2 appears first on the text than Figure 1?

See point 9 Reviewer#1 for answer.

5 - Normally, the accelerated stability studies are conducted during 3 months at 40°C. Why the authors selected 25°? Did the authors controlled the humidity?

We thank the reviewer for this observation, there was a mistake, the stability studies were conducted at 40°C. The humidity grade was comprised between 70-75% RH. This missed information is now included in the manuscript.

6 - Point 4 should be discussion and conclusion

As suggested by Reviewer #2, point 4 was changed accordingly.

Hoping that now the manuscript could be suitable for publication, I send my best regards

Dr. Elisabetta Esposito

1 **Monoolein liquid crystalline phases for topical delivery of crocetin**

2

3 Elisabetta Esposito^{a*}, Federica Carducci^b, Paolo Mariani^b, Nicolas Huang^c, Fanny
4 Simelière^c, Rita Cortesi^{a*}, Giuseppe Romeo^d and Carmelo Puglia^d

5

6 ^a*Department of Life Sciences and Biotechnologies, University of Ferrara, I-44121 Ferrara,*
7 *Italy*

8

9 ^b*Department of Life and Environmental Sciences, Università Politecnica delle Marche, I-*
10 *60131 Ancona, Italy*

11

12 ^c*Institut Galien Paris-Sud, CNRS, Faculté de Pharmacie, Université Paris-Sud, Univ Paris-*
13 *Saclay, France*

14

15 ^d*Department of Drug Science, University of Catania, I-95125-Catania, Italy*

16

17 * Correspondence to: Dr Elisabetta Esposito and Prof Rita Cortesi
18 Dipartimento SVEB
19 Via Fossato di Mortara, 19
20 I-44121 Ferrara, Italy
21 Tel. +39/0532/455259
22 Fax. +39/0532/455953
23 e-mail ese@unife.it; crt@unife.it

24 Statistical summary

25 total number of words (excluding figure captions) **5995**; Tables: 3, Figures: 5.

26 **Abstract**

27 The present investigation concerns the production and characterization of monoolein-
28 water systems designed for cutaneous administration of crocetin. The different monoolein
29 crystalline phases forming in the presence of crocetin as a function of added water have
30 been investigated by x-ray and polarized light microscopy. Franz cell **was** employed to
31 compare *in vitro* the crocetin diffusion from selected monoolein water systems containing
32 95, 90 or 75 % w/w of monoolein, while to investigate the performance of monoolein-water
33 as transdermal delivery systems, *in vivo* studies, based on tape stripping were performed.
34 **The presence of micellar, lamellar and Q230 phases was found** in the case of systems
35 containing monoolein 95, 90 and 75% **w/w** respectively, with a viscosity almost directly
36 proportional to the amount of added water. The higher the amount of water, the longer the
37 crocetin stability, while its diffusion was slower in the case of more viscous systems. Tape
38 stripping results indicated a more rapid depletion of crocetin on *stratum corneum* in the
39 case of systems characterized by cubic phases, followed by micellar and lamellar ones.
40 This behaviour could be related to a more rapid drug penetration throughout the deeper
41 skin strata.

42

43 **Keywords:** crocetin, monoolein, polarized light microscopy, small angle x-ray scattering,
44 diffusion, tape-stripping.

45 **Abbreviations :** Crocetin (CRT) ; small angle x-ray scattering (SAXS).

46

47 1. Introduction

48 Amphiphilic polar lipids, such as monoglycerides, can form various crystalline phases in
49 the presence of different amounts of water. These lipids self-associate, depending on the
50 temperature and aqueous content, forming reversed micellar (L₂), lamellar (L_α), or
51 bicontinuous cubic phases (C) in which the hydrocarbon chains assume a liquid-like
52 conformation [1-2]. Particularly, glycerol monooleate (monoolein), a nontoxic,
53 biodegradable and biocompatible material commonly used as emulsifying agent and food
54 additive, is one of the monoglycerides most widely employed to form liquid crystalline
55 formulations [3-5]. Different studies have attributed to monoolein a penetration enhancer
56 activity when applied on skin, probably due to a temporary and reversible disruption of the
57 lamellar structure of the lipid bilayer in the *stratum corneum* caused by an increase in
58 intercellular lipid fluidity [6-8]. In the presence of tiny amounts of water (5-10%, w/w),
59 monoolein forms reversed micelles or lamellar phases, while when more water is added
60 (~15-40%) a cubic phase region dominates. This highly viscous isotropic phase is defined
61 bicontinuous, being constituted of a curved three-dimensional bilayer, separating two
62 congruent water channel networks [9, 10].

63 Many authors have focused their attention on the relevance of the lipid crystalline phases
64 for drug delivery [11-13]. Indeed, the presence of a lipid and an aqueous domain confers
65 special properties to the crystalline phases, such as the ability to solubilize hydrophilic,
66 hydrophobic, and amphiphilic substances [14-16]. In addition, liquid crystalline phases
67 protect drugs from degradation, control drug release and possess hydrating power [17-20].

68 Crocetin (CRT) is an active molecule originally discovered in dried stigma of *Crocus*
69 *Sativus* (Saffron), recently taken in consideration in biomedical research because of its
70 pharmacological activities, such as antitumoral, antioxidant, antihypertensive,
71 antiatherosclerotic and antidepressant [21-25].

72 In *Crocus Sativus* the chromoplast zeaxanthine cleavage dioxygenase first generates CRT
73 dialdehyde, then converted into CRT by an aldehyde oxydo-reductase and transformed to
74 the glucosylate derivative crocin by a glucosyl transferase [26,27]. Interestingly, recent
75 studies have indicated the potential of CRT against skin damage induced by UV-A. Indeed,
76 CRT reduces the oxidative stress by decreasing reactive oxygen species production and
77 cell apoptosis [28]. Nonetheless, the antioxidant power of CRT is unfortunately associated
78 to a low stability, especially in the presence of heat, oxygen, light and acids [29]. In the
79 present study, monoolein-water systems have been designed and investigated as vehicles
80 for CRT with the aim to find cutaneous systems suitable to treat skin pathologies and to
81 protect skin against UV-induced skin damage. The different monoolein mesophases have
82 been characterized by small angle x-ray scattering (SAXS), polarized light microscopy and
83 rheological measurements. Tape stripping experiments enabled to shed light on the CRT
84 distribution on stratum corneum after application of different monoolein-water systems on
85 the skin.

86

87 **2. Materials and methods**

88

89 **2.1. Materials**

90

91 Crocin and glucosidase enzyme were purchased from Merck KGaA (Darmstadt,
92 Germany). 2,3-Dihydroxypropyl oleate, Glycerol monooleate, RYLO MG 19 (monoolein)
93 was a gift from Danisco Cultor (Grindsted, Denmark). Solvents and other chemicals were
94 purchased from Merck KGaA.

95

96 **2.2 Preparation of crocetin**

97 Crocetin, (*2E,4E,6E,8E,10E,12E,14E*)-2,6,11,15-Tetramethylhexadeca-2,4,6,8,10,12,14-
98 heptaenedioic acid, CRT), was obtained in our laboratory by alkaline hydrolysis of crocin,
99 the protocol is reported in the supplementary materials section.

100

101 **2.3. Production of monoolein-water samples**

102 Monoolein based formulations were prepared by adding different amounts of water
103 (ranging from 5 and 25% w/w) to molten monoolein at 42°C [30,31]. When a uniform
104 mixture was formed under stirring, the containers were sealed, to avoid water evaporation,
105 and placed in an oven at 42°C for 72 h. Afterwards the samples have been stirred by hand
106 until uniform aspect. In the case of CRT containing monoolein-water systems, CRT (0.02
107 % w/v) has been added to the samples before placing in the oven. Sample compositions
108 and acronyms are reported in Table 1.

109 **Table 1:** Composition of the studied monoolein based formulations
 110

<i>Formulations</i>	<i>Monoolein (% w/w)</i>	<i>Water (% w/w)</i>	<i>Crocetin (% w/v)*</i>
M-75	75	25	-
M-80	80	20	-
M-85	85	15	-
M-90	90	10	-
M-95	95	5	-
M-75-CRT	75	25	0.02
M-80-CRT	80	20	0.02
M-85-CRT	85	15	0.02
M-90-CRT	90	10	0.02
M-95-CRT	95	5	0.02

111 *with respect to the volume of the formulations
 112
 113

114 **2.4 X-ray characterization**

115 **Small angle X-ray scattering (SAXS)** experiments were performed at the Elettra
 116 synchrotron radiation facility (Basovizza, Trieste) at the AustroSAXS beamline. Samples
 117 were held on a flat watertight holder, to allow fixed composition studies and to avoid
 118 mechanical stress that could interfere or increase anisotropy. Experiments were performed
 119 at 37 °C on different monoolein formulations in the presence and in the absence of CRT.
 120 The investigated q-range ($q = 4\pi \sin \theta/\lambda$, where 2θ is the scattering angle and $\lambda = 1.54 \text{ \AA}$)

121 the X ray wavelength) was 1-4 nm⁻¹. The observed Bragg peaks were indexed considering
122 the different symmetries commonly observed in lipid polymorphism [32].

123

124 **2.5 Polarized light microscopy**

125 Monoolein-water samples were examined through a polarized light microscope (Ortholux
126 POL-MK, Carl Zeiss, Oberkochen, Germany) to verify texture and anisotropy of the liquid
127 crystalline phases. The prepared **sample was** deposited on a glass slide using a spatula,
128 to avoid any possible mechanical stress that could force the alignment of the molecules
129 inside the sample. Once the sample was loaded, the coverslip was sealed using silicone
130 grease, to ensure the maintenance of the monoolein hydration. For every type of
131 formulation, three different samples were observed.

132

133 **2.6 Rheological measurements**

134 Rheological measurements were performed with an AR-G2 controlled-stress rotational
135 rheometer (TA Instruments, USA). The geometry used was an aluminium cone-plate **(40**
136 **mm diameter, 1° cone angle, 28 μm truncation gap)**. Flow curves were obtained by a flow
137 sweep protocol: after a 2-min conditioning time, shear rate was increased from 0.1 to 2000
138 s⁻¹ for a total duration of 180 s. The temperature was maintained at 37 °C and controlled
139 with a Peltier plate. Measurements were performed in triplicate at least for each sample, to
140 ensure reproducibility.

141

142 **2.7 Spreadability test**

143 **The spreading capacity of selected formulations, namely M-90 and M-95, was evaluated**
144 **as follows. One hundred mg of preparation was placed on a Petri dish (3 cm diameter) and**
145 **pressed by another glass dish on which a 500-g mass was positioned. Taken the time by**

146 which the formulation fills the entire dish, the following equation was used to calculate the
147 spreadability (S) value.

$$148 \quad S = m \times l / t \quad (1)$$

149 where m is the weight (g) tied on the upper plate, l is the diameter (cm) of the glass plate,
150 and t is the time (s) taken for the gel to fill the entire diameter. The spreadability test was
151 performed thrice and the mean values \pm standard deviations were calculated.

152

153 **2.8 CRT content**

154 The content of CRT in monoolein-water systems was determined by dissolving an aliquot
155 of sample in dimethyl sulfoxide (1:10, w/w) under magnetic stirring (ARE-6 heating
156 magnetic stirrer, VELP Scientifica, Usmate, Italy) for 1 hour in amber glass vials to avoid
157 CRT photodegradation.

158 Samples were then filtered by nylon filters with 0.45 μm pore diameter (Whatman™,
159 Germany) and finally diluted with methanol (1:10, v/v). The filtrate was then analyzed by
160 high performance liquid chromatography (HPLC). Determinations were performed using a
161 quaternary pump (Agilent Technologies 1200 series, USA) an UV-detector operating at
162 423 nm, and a 7125 Rheodyne injection valve with a 50 μl loop. Samples were loaded on
163 a stainless-steel C-18 reverse-phase column (15 \times 0.46 cm) packed with 5 μm particles
164 (Grace® - Alltima, Alltech, USA).

165 Elution was performed with a mobile phase containing methanol:water (80:20, v/v); at a
166 flow rate of 0.8 ml/min, retention time was 3.8 min. The method was validated for linearity
167 ($R^2 = 0.994$), repeatability (relative standard deviation 0.02%, n=6 injections) and limit of
168 quantification (0.03 $\mu\text{g/ml}$).

169 CRT content was expressed as percentage of the total amount added to monoolein-water
170 for system production.

171

172 **2.9 Prediction of long-term stability**

173 The stability of CRT was assessed in stored glass containers at 40°C for 3 months, 70-
174 75% RH.

175 Chemical stability was evaluated, determining CRT content by HPLC analyses as above
176 reported. Shelf life values were calculated as below reported [33].

177 Log (CRT residual content, %) was plotted against time and the slopes (m) were
178 calculated by linear regression.

179 The slopes (m) were then substituted into the following equation for the determination of k
180 values:

181 $k = m \times 2.303$ (2)

182 Shelf life values (the time for 10% loss, t_{90}) and half-life (the time for 50% loss, $t_{1/2}$) were
183 then calculated by the following equations:

184 $t_{90} = 0.105/k$ (3)

185 $t_{1/2} = 0.693/k$ (4)

186

187 **2.10 In vitro diffusion experiments**

188 CRT diffusion experiments were performed by Franz-type diffusion cells supplied by
189 Vetrotecnica (Padova, Italy) associated to nylon membranes (Merck Millipore, 0.45 μm
190 pore size).

191 The exposed membrane area was 0.78 cm^2 area (1 cm diameter orifice). The receptor
192 compartment contained 5 ml of a mixture of phosphate buffer 60 mM pH 7.4 and ethanol
193 (50:50, v/v). This solution was stirred with the help of a magnetic bar at 500 rpm and
194 thermostated at $32 \pm 1^\circ\text{C}$ during all the experiments [34,35].

195 Approximately 1 g of M-75-CRT, M-90-CRT or M-95-CRT was placed on the membrane in
196 the donor compartment and the latter was sealed to avoid evaporation. At predetermined

197 time intervals comprised between 0 and 24 h, samples (0.15 ml) of receptor phase solution
198 were withdrawn and the CRT concentration in the receptor phase was measured using
199 HPLC. Each removed sample was replaced with an equal volume of fresh receptor phase.
200 The CRT concentrations were determined six times in independent experiments and the
201 mean values \pm standard deviations were calculated. The mean values were then plotted
202 as a function of time. The flux coefficients were computed from the linear portion of the
203 accumulation curve calculating the curve slopes and dividing them by the CRT
204 concentration in the monoolein based formulation (expressed in mg/ml).

205

206 **2.11 Tape stripping**

207

208 **2.11.1 Volunteers recruitment**

209 Ten volunteers of both sexes in the age range 25–55 years were recruited after medical
210 screening, including the filling of a health questionnaire followed by physical examination
211 of the application sites. Informed consent was obtained from all individual participants
212 included in the study. The participants did not suffer from any ailment and were not on any
213 medication at the time of the study. They were rested for 15 min prior to the experiments
214 and room conditions were set at 22 ± 2 °C and 40–50% relative humidity.

215

216 **2.11.2 Experimental protocol**

217 The tape stripping protocol was approved by the Ethics Committee of the University of
218 Ferrara, Italy (study number: 170986) and conducted in accordance with the Code of
219 Ethics of the World Medical Association (Helsinki Declaration 1964) and its later
220 amendments for experiments involving humans.

221 For each subject, ten sites on the ventral surface of forearms were defined using a
222 rectangular template (2 cm²) and demarcated with permanent ink. One of the ten sites of

223 each forearm was used as control, three sites were treated with 80 mg of M-75-CRT, three
224 sites with 80 mg of M-90-CRT and the remaining three with 80 mg of M-95-CRT. The
225 preparations were spread uniformly by means of a solid glass rod, thereafter the sites
226 were occluded for 1 h using rectangular plasters especially designed for skin occlusion.
227 Afterwards the residual formulations were removed by gently wiping with cotton balls
228 (different for each pretreated site). Ten individual 2 cm² squares of adhesive tape (Scotch
229 Book Tape 845, 3M) were utilized to sequentially tape-strip the *stratum corneum* on the
230 application sites. Particularly *stratum corneum* in each pretreated site was removed at 0.5
231 (t_{0.5}), 3 (t₃) and 6 (t₆) h after formulation removal.
232 Each adhesive square, before and after skin tape stripping, was weighed on a semi-
233 microbalance (sensitivity 1mg, Sartorius model ME415S, Goettingen, Germany) to quantify
234 the weight of removed *stratum corneum*. After each stripping, the tapes were put in the
235 same vial containing 2 ml of the HPLC mobile phase methanol:water (80:20 v/v) and
236 subjected to vortical stirring over 30 s. The extracted CRT was then quantified by HPLC.
237 The recovery of CRT was validated by spiking tape-stripped samples of untreated *stratum*
238 *corneum* with 2 ml of a mobile phase containing CRT 5 mg/ml [36].

239

240 2.11.3 Statistical Analysis

241 Statistical differences of *in vivo* data were determined using repeated-measures analysis
242 of variance (ANOVA) followed by the Bonferroni-Dunn post hoc pairwise comparison
243 procedure. The employed software was Prism 5.0, Graph Pad Software Inc. (La Jolla, CA -
244 USA). A probability of less than 0.05 is considered significant in this study.

245 **3. Results**

246

247 **3.1. Synthesis and characterization of crocetin**

248 CRT is difficult to obtain in high yield and with a good degree of purity, thus it is hardly
249 available commercially. For this reason, the compound was obtained in our laboratory,
250 exploiting some experimental techniques described in **supplementary materials** section.

251 CRT was obtained by alkaline hydrolysis, its ¹H-NMR spectrum showed a doublet (d, δ =
252 7.21, J = 9.6 Hz) and a multiplet (m, δ = 6.90 – 6.44) related to hydrogens of the polyenic
253 chain and two singlets related to hydrogens of the methyl groups placed symmetrically at
254 the 2- and 15-positions (s, δ = 1.98) and at the 6- and 11-positions (s, δ = 1.92) of the
255 chain. The ¹H-NMR spectrum signals relative to the CRT sample coincided with those
256 estimated by the simulation program ACD/C + H NMR Predictors (version 11.01) and with
257 literature data [37].

258

259 **3.2 Production of monoolein-water systems**

260 A simple protocol was adopted to produce monoolein-water samples, notably the addition
261 of small percentage of water to melted monoolein followed by equilibration at 42°C
262 resulted in transparent systems with different consistency, depending on the amount of
263 added water (Fig S1A, supplementary material). To assess CRT solubility, different
264 amounts of the drug (0.2-1 mg/ml) have been added to the monoolein-water systems
265 before equilibration at 42°C. The transparency of the systems enabled to detect the
266 presence of yellow crystals in the case of samples containing CRT > 0.2 mg/ml, while a
267 homogeneous yellow **colouring** characterized samples with CRT 0.2 mg/ml. **For all the**
268 **tested monoolein-water systems the CRT content, evaluated after disaggregation and**
269 **HPLC analyses, was 98 % \pm 0.2 with respect to the weight of CRT added to the**
270 **monoolein-water mixture.**


271

272 **3.4 X-ray scattering analysis**

273 X-ray diffraction experiments were performed to investigate the structural properties of the
274 monoolein formulations. A few results are shown in Fig. 1, while details about phase
275 symmetry and unit cell values are reported in Table 2.

276 The X-ray diffraction scattering profiles for M-95 and M-95-CRT samples show a large
277 band centered at about 1.8 nm^{-1} . In good agreement with the monoolein-water phase
278 diagrams [32,38], the large band confirms the presence of a micellar phase in both
279 systems. A narrow peak is indeed overlapped on this band in the case of the more
280 hydrated M-90 and M-90-CRT samples, indicating the formation of the lamellar phase. For
281 higher water concentrations, several Bragg peaks are observed; both in the absence and
282 in the presence of CRT, the spacing of the reflections has been indexed considering the
283 space group Q230. The characteristic profile then indicates the formation of the cubic Ia3d
284 phase in the more hydrated conditions investigated. A schematic representation of the
285 different lyotropic phases observed in the present systems is reported in Fig S1B
286 (supplementary material). It should be mentioned that the Ia3d cubic phase is bicontinuous
287 and exhibits two 3-D networks of connected aqueous rods, co-planarly joined 3 by 3 [39].
288 Notably, no differences in the X-ray diffraction profiles are detected in the presence of
289 CRT, disregarding the case of M-85-CRT sample. In this latest case, Bragg peaks appear
290 doubled, probably due to a low homogeneity of the sample, whose concentration
291 corresponds to the lamellar-to-Ia3d cubic phase boundary. Thus, CRT does not modify the
292 structural organization of monoolein. Slight changes have been however detected in the
293 unit cell parameters, which appear to be systematically reduced in the presence of CRT
294 (Table 2), suggesting a small dehydration of the lipid layer.

295




308 **Figure 1.** SAXS profiles observed on monoolein, both in the absence (A) and in the presence (B) of CRT
 309 0.02% w/v, measured at 37°C. The black arrow indicates the direction of the increasing concentration of
 310 water. Curves were separated using offset for clarity.

312 3.5 Polarized light microscopy characterization

313 Polarized light microscopy enables to easily characterize the sample quality and to screen
 314 the lyotropic liquid crystalline phases in lipid-water systems. Indeed, lamellar and
 315 hexagonal phases evidence birefringence textures, as real crystals, while lack of
 316 birefringence indicates that the phase is cubic or liquid [40]. Fig 2 shows polarized light
 317 microscopy images of M-85-CRT and M-90-CRT samples. In the case of M-85-CRT (Fig.
 318 1A), birefringent anisotropic textures can be appreciated, probably because of the
 319 presence of phase coexistence. Instead, in the case of M-90-CRT (Fig. 1B) as well as M-
 320 95-CRT (not shown), flower-like structures typical of a lamellar phase organization can be
 321 observed [41]. Similar images were taken in the case of samples produced in the absence

322 of CRT. In the case of the other more hydrated monoolein-water systems (from 85% to
323 75%), no textures have been detected, confirming the presence of a cubic phase.




324

325 **Figure 2.** Polarized light microscopy images of M-85-CRT (A), and M-90-CRT (B). Observations were made
326 using a magnification 10x.

327 3.6 Rheological analysis

328 Rheology gives valuable information about the lipid crystalline phases [42-44]. A
329 comprehensive rheological characterization can be very useful for their practical
330 applications and for the development of suitable formulations.

331 Results of rheological measurements performed on plain monoolein and on monoolein-
332 water systems, in the absence or in the presence of CRT, are shown in Fig 3, while
333 viscosity values measured at 10 s^{-1} are reported in Table 2.



355 **Figure 3.** Rheological flow curves of the indicated monoolein based formulations produced in the absence
 356 (A) or in the presence (B) of CRT. Measurements were performed at 37°C. The geometry used was an
 357 aluminium cone-plate. Flow curves were obtained by increasing the shear rate from 0.01 s⁻¹ to 5000 s⁻¹ with
 358 5 points per decade, each point was maintained for a duration of 180 s to perform measurements in the
 359 permanent regime. Data are the means of 3 analyses on different batches of the same type of formulations.

360 **Table 2.** Macroscopic aspect, viscosity, phase symmetry and unit cell of monoolein
 361 based formulations measured at 37°C.
 362

<i>Formulations</i>	<i>Macroscopic aspect</i>	<i>Viscosity* (Pa.s) ± 5%</i>	<i>Phase symmetry^a</i>	<i>Unit cell^a (Å) ± 0.5</i>
M-75	gel	1435	cubic Ia3d (Q230)	120.7
M-80	gel	3514	cubic Ia3d (Q230)	107.4
M-85	gel	3819	cubic Ia3d (Q230)	99.9
M-90	viscous	4.6	lamellar/micellar	37.6
M-95	liquid	0.3	micellar	34 (broad)
M-75-CRT	gel	1785	cubic Ia3d (Q230)	118.9
M-80-CRT	gel	3224	cubic Ia3d (Q230)	106.7
M-85-CRT	gel	3927	cubic Ia3d (Q230)	99.7
M-90-CRT	viscous	5.2	lamellar/micellar	37.4
M-95-CRT	liquid	0.3	micellar	34 (broad)

363 *shear rate 10^{-1} s⁻¹; a: as determined by X-ray scattering. Monoolein based formulations acronyms
 364 are explained in Table 1.
 365

366 Viscosity curves show that M-90, M-85, M-80 and M-75 were strongly shear-thinning.

367 Indeed, for these samples an appreciable decrease of the viscosity was detectable
 368 increasing the shear rate. Generally, an increase of water led to an increase of viscosity,
 369 particularly the increase was dramatic passing from M-95 to M-90, or from M-90 to M-85.

370 Viscosity curves of M-85 and M-80 are alike and **could be not distinguishable**, indeed the
 371 structure for these two samples **displayed** the same flow behavior. The viscosity values of
 372 M-75 are slightly smaller than M-85 and M-80. M-95 and plain monoolein, employed as
 373 control, **showed** a slight shear-thinning behavior at low shear rate (below ≈ 1 s⁻¹) and a

374 Newtonian behavior at higher shear rates. The presence of CRT did not influence the
375 viscosity, as indicated by superimposable profiles of Fig. 3A, 3B and viscosity data
376 reported in Table 2. Upward and downward viscosity flow sweeps have been performed on
377 M-80, M-90, M-95 and M-100 samples (supplementary material, Fig. S2). The samples
378 were all weakly thixotropic and slightly more thixotropic in the case of M-90 (Fig. S2B) at
379 low shear rates.

380

381 **3.7 Spreadability of monoolein-water systems**

382 Spreadability of monoolein-water systems was studied to select the systems suitable for
383 administration on skin. Indeed, this parameter is essential for cutaneous administration
384 since it influences extrudability from the package, uniform application and drug therapeutic
385 efficacy [45,46]. Among the systems, only those characterized by micellar or lamellar
386 mesophases, i.e. M-95 and M-90, were easily spreadable (spreadability ratio M-95/M-90
387 1.6:1) (Table S1, supplementary materials). Monoolein-water systems based on cubic
388 phases were not easily spreadable, apart from M-75, characterized by a viscosity lower
389 than M-85 and M-80. The presence of CRT did not modify the system spreadability.
390 Noteworthy, further studies have been focused on M-95-CRT, M-90-CRT and on M-75-
391 CRT, selected to compare the micellar, lamellar and cubic phase performances as delivery
392 system for CRT.

393

394 **3.8 CRT stability**

395 To assess shelf life stability, CRT content of monoolein-water systems was determined as
396 a function of time and expressed as percentage of the total amount used for the
397 preparation (Fig. S3, supplementary materials). After 3 months CRT content followed the
398 order M-75-CRT>M-90-CRT> M-95-CRT (CRT respectively 85, 71 and 54 % with respect

399 to the drug content detected after sample preparation). Table 3 reports shelf life (t_{90}) and
400 half-life ($t_{1/2}$) values calculated by equations (2) and (3).

401

402 **Table 3.** Shelf life data and CRT fluxes from the indicated monoolein based formulations

403

<i>Formulations</i>	m^a	k^b	$t_{90}^b(\text{days})$	$t_{1/2}^b(\text{days})$	$\text{flux}^c (\text{cm/h} \cdot 10^3)$
M-75-CRT	-0.0007	0.0017	58.67	389.32	2.37
M-90-CRT	-0.0016	0.0036	28.37	187.29	3.67
M-95-CRT	-0.0027	0.0063	16.51	109.1	4.37

404 a: slope of the line of log (CRT residual content %) kinetic, calculated as the mean of 3 independent
405 determinations, s.d. $\leq 2\%$; b: K , t_{90} and $t_{1/2}$ were calculated following equations. 1, 2 and 3
406 respectively; c: calculated by Franz cell experiment, considering the slope of the line of CRT diffusion
407 and its concentration in the monoolein formulations. Monoolein based formulations acronyms are
408 explained in Table 1.

409

410 It was found that $t_{1/2}$ value of CRT exceeded 1 year in the case of M-75-CRT, 6 months in
411 the case of M-90-CRT and 3 months in the case of M-95-CRT. All data were statistically
412 significant ($p < 0.0001$).

413 All monoolein/water systems maintained their physical appearance with time, without
414 phase separation phenomena also after six months from production.

415


416 **3.9 In vitro CRT diffusion**

417 The diffusion of CRT included in M-75-CRT, M-90-CRT and M-95-CRT was compared by
418 Franz cell experiments. Notably the receptor phase was constituted of a phosphate
419 buffer/ethanol 50:50 (v/v) mixture to allow the establishment of the sink conditions and to
420 sustain permeant solubilization [34]. Fig 4 shows the diffusion kinetics **corresponding to**
421 **the linear part of the profile (from 0 to 8 h)**, while the flux values are reported in Table 3.

422 The diffusion of CRT was more controlled in the case of M-75-CRT with respect to the

423 other forms. Indeed, M-75-CRT flux value was almost half than M-95-CRT and 2/3 with
424 respect to M/90-CRT.

425



426

427 **Figure 4.** In vitro diffusion profiles of CUR from M-75-CRT (squares), M-90-CRT (circles) and M-95-CRT
428 (crosses). Experiments were performed by Franz cell associated to nylon membranes. Data represent the
429 mean of six independent experiments \pm S.D.

430

431 3.10 Tape-stripping evaluation

432 A monocentric observational experiment was conducted by tape stripping for quantifying
433 CRT presence in the *stratum corneum* after cutaneous administration of M-75-CRT, M-90-
434 CRT and M-95-CRT [36,47]. Formulations have been applied on the forearms following the
435 scheme depicted in data in supplementary material **Fig. S4**. Portions of *stratum corneum*
436 have been stripped at $t_{0.5}$, t_3 and t_6 . Tape stripping results are summarized in Fig.5. A

437 general depletion in the amount of CRT in the *stratum corneum* was observed by time.
438 Notably, in the case of M-75-CRT, the CRT amount at $t_{0.5}$ was 3.5 and 2-fold higher with
439 respect to M-90-CRT and M-95-CRT respectively (Fig 5A). Fig 5B shows a comparative
440 evaluation of the CRT level present in *stratum corneum* at t_3 and t_6 with respect to $t_{0.5}$. A
441 depletion of CRT more pronounced in the case of M-75-CRT was observed, followed by
442 M-90-CRT and M-95-CRT (Fig 5B). The CRT amounts detected in the *stratum corneum* at
443 $t_{0.5}$ and t_3 were significantly different. The extraction efficiency of CRT was 97.8 ± 0.4 %
444 ($n= 3$).

445

446 **4. Discussion and conclusions**

447 The powerful activity of CRT makes this molecule interesting both for pharmaceutical, as
448 well as for cosmeceutical applications. We succeeded to obtain this molecule by alkaline
449 hydrolysis of crocin. To find vehicles able to solubilize and deliver CRT through the skin,
450 monoolein-water systems were investigated. In these captivating systems, monoolein
451 disposes in various forms as a function of water content, resulting in different crystalline
452 mesophases. SAXS characterization of monoolein water-systems enabled to identify
453 micellar, lamellar or Q 230 phases. Namely these latest mesophases were found for 15-25
454 % water content. These results confirm previously findings of other authors and agree well
455 with polarized light microscopy observations and rheological measurements [30,43,44].
456 Indeed, birefringence of M-90, M-90-CRT, M-95 and M-95-CRT samples allowed to
457 observe flower-like structures typical of lamellar phases, while samples with 20-25 % water
458 content did not transmit the light, being characterized by isotropic cubic phases.

459 Viscosity profiles are very intriguing, indeed monoolein-water samples showed a non-
460 continuous behavior under dilution (Fig. 3A and 3B). Namely, an almost Newtonian
461 behavior was observed for 0-5% water content, while samples containing 10-25 % of water

462 were strongly shear-thinning, suggesting an important structure rearrangement under
463 shear. Such viscosity behavior can be directly related to the structure of the various
464 monoolein phases, having a different degree of entanglement. Indeed, the disordered
465 isotropic micellar phase (M-95), occurring in very dehydrated conditions, was very fluid
466 (viscosity < 1 Pa·s), while an increase of water concentration led to lamellar phase formation
467 (M-90), characterized by a 1-D ordered structure and a dramatically higher viscosity (1-100
468 Pa·s). A second remarkable change in viscosity (100-100000 Pa·s) was observed in the
469 case of cubic Ia3d phase, showing a 3-D ordered structure, thus particularly viscous.
470 Notably, viscosity values of samples in the Ia3d cubic phase (M-85, M-80 and M-75)
471 slightly decreased, as a function of water content. It can be suggested that under hydration
472 the cubic phase softens because of the changes in the monoolein structural parameters.
473 Indeed, with the same degree of entanglement, the lipid bilayer curvature, the area-per-
474 molecule at the lipid/water interface and the hydrocarbon chain packing should play a key
475 role on the mechanical properties of the phase [32].

476 Regarding chemical stability, monoolein-water systems preparation did not induce
477 degradation of CRT, as indicated by HPLC analyses of systems after sample
478 disaggregation.

479 Shelf life and Franz cell studies evidenced that the system characterized by cubic phases
480 better **controlled** stability and diffusion of CRT with respect to micellar and lamellar based
481 systems. These differences could be attributed both to the viscosity and to the
482 crystallographic structure of the systems, indeed, the viscosity of liquid crystalline phases
483 can affect the diffusion kinetics of the solubilized active molecules. Notably, the
484 bicontinuous cubic phases are more rigid than the lamellar ones, described as plastic
485 fluids undergoing yielding [43,44].

486 Tape stripping experiments enabled to shed light on the performance of monoolein
487 mesophases as cutaneous delivery systems for CRT. At the first-time interval ($t_{0.5}$), the
488 higher CRT amount found in *stratum corneum* in the case of M-75-CRT could account for
489 its higher viscosity that could initially prolong its permanence on skin with respect to M-90-
490 CRT and M-95-CRT. It should be considered that monoolein can alter the skin barrier
491 properties due to interactions with the intercellular lipids in the *stratum corneum*. These
492 alterations of lipid packing lead to hydration of stratum corneum and disorganization of the
493 lipid bilayers [7,18]. At t_3 and t_6 , it is noteworthy that the CRT depletion was not ascribable
494 to high monoolein/water ratio, indeed in the case of micellar (M-95-CRT) or lamellar
495 phases (M-90-CRT), CRT depletion was less pronounced with respect to the cubic phase
496 system (M-75-CRT). The more pronounced depletion of CRT found in the case of M-75-
497 CRT could be justified by the hypothesis of a penetration enhancement effect, due to an
498 interaction between cubic phase system and *stratum corneum* lipids. This hypothesis is
499 corroborated by some studies indicating a higher skin permeability exerted by cubic
500 phases with respect to lamellar ones [48] while others suggested a similarity between the
501 cubic phase structure and the structure of the stratum corneum [49]. Thus, it could be
502 suggested that monoolein organized in cubic mesophases could mix with *stratum corneum*
503 lipids and induce an intercellular lipid disorder, finally promoting skin uptake.

504 On the other hand, it can be asserted that the lower viscosity of M-90-CRT and M-95-CRT
505 initially promotes CRT penetration through *stratum corneum* ($t_{0.5}$), afterwards the drug is
506 slowly subtracted, suggesting the formation of a monoolein depot within the *stratum*
507 *corneum* lipids. At this regard, it should be considered that CRT should long remain in the
508 upper skin strata to exert its skin protection against UV damage, thus a prolong
509 permanence is desirable, while a deeper CRT penetration should be avoided. Moreover, it
510 is noteworthy that **rheological properties (shear-thinning behaviour) and spreadability of**

511 the lamellar phase make it more appropriate for cutaneous application with respect to the
512 cubic one.

513 Eventually this study has demonstrated the suitability of monoolein-water systems as
514 cutaneous vehicles for CRT, nonetheless further in vivo studies are needed (i) to verify the
515 antioxidant activity and skin protection of the different CRT containing systems, (ii) to point
516 out the mechanism of monoolein mesophases and CRT distribution in the different skin
517 layers.

518

519 **Conflict of interest**

520 The authors declare that there is no conflict of interests.

521

522 **Acknowledgements**

523 The authors are grateful to Maddalena Sguizzato and Debora Santonocito for conducting
524 in vitro diffusion experiments and CRT synthesis.

525 **References**

- 526 [1] J.M. Seddon, R.H. Templer, Polymorphism of lipid-water systems, in: R. Lipowsky, E.
527 Sackmann (Eds.), Handbook of Biological Physics, Volume 1, Elsevier Science Publishers
528 B.V., N.Y., United States, 1995.
- 529 [2] R. Mezzenga, Physics of self-assembly of lyotropic liquid crystals, in: Nissim Garti,
530 Ponisseril Somasundaran, Raffaele Mezzenga (Eds.), Self-assembled supramolecular
531 architectures: lyotropic liquid crystals, John Wiley & Sons Inc. Hoboken, New Jersey 2012
532 edited by, pp. 19-35.
- 533 [3] A. Ganem-Quintanar, D. Quintanar-Guerrero, P. Buri, Monoolein: a review of the
534 pharmaceutical applications, Drug. Dev. Ind. Pharm., 26 (2000) 809-820.
- 535 [4] P. Mariani, F. Rustichelli, L. Saturni, L. Cordone, Stabilization of the monoolein Pn3m
536 cubic structure on trehalose glasses, Eur. Biophys. J., 28 (1999) 294-301.
- 537 [5] V. Chandrashekar, W.W. Kulkarni, I.-S. Guillermo, S. Engelskirchen, S. Ahuallia,
538 Monoolein: a magic lipid?, Phys. Chem. Chem. Phys., 13 (2011) 3004-3021.
- 539 [6] L.B. Lopes, J.H. Collett, M.V. Bentley, Topical delivery of cyclosporin A: an in vitro study
540 using monoolein as a penetration enhancer, Eur. J. Pharm. Biopharm., 60 (2005) 25-30.
- 541 [7] L.B. Lopes, F.F. Speretta, M. Bentley, Enhancement of skin penetration of vitamin K
542 using monoolein-based liquid crystalline systems, Eur. J. Pharm. Sci., 32 (2007) 209-215.
- 543 [8] S. Milak, A. Zimmer, Glycerol monooleate liquid crystalline phases used in drug delivery
544 systems, Int. J. Pharm., 478 (2015) 569-587.
- 545 [9] K. Larsson, Cubic lipid-water phases: structures and biomembrane aspects, J. Phys.
546 Chem., 93 (1989) 7304-7314.
- 547 [10] K. Larsson, Aqueous dispersions of cubic lipid-water phases, Curr. Opin. Colloid
548 Interface Sci., 5 (2000) 64-69.

- 549 [11] M.G. Lara, M.V.L.B. Bentley, J.H. Collett, In vitro drug release mechanism and drug
550 loading studies of cubic phase gels, *Int. J. Pharm.*, 293 (2005) 241-250.
- 551 [12] A.R. Ahmed, A. Dashevsky, R. Bodmeier, Drug release from and sterilization of in situ
552 cubic phase forming monoglyceride drug delivery systems, *Eur. J. Pharm. Biopharm.*, 75
553 (2010) 375-380.
- 554 [13] J.C. Shah, Y. Sadhale, D.M. Chilukuri, Cubic phase gels as drug delivery systems,
555 *Adv. Drug Deliv. Rev.*, 47 (2001) 229-250.
- 556 [14] A. Zabara, R. Mezzenga, Controlling molecular transport and sustained drug release
557 in lipid-based liquid crystalline mesophases, *J. Control. Rel.*, 188 (2014) 31-43.
- 558 [15] S.B. Rizwan, B.J. Boyd, T. Rades, S. Hook, Bicontinuous cubic liquid crystals as
559 sustained delivery systems for peptides and proteins, *Expert Opin. Drug Deliv.*, 7 (2010)
560 1133-1144.
- 561 [16] C. Guo, J. Wang, F. Cao, R.J. Lee, G. Zhai, Lyotropic liquid crystal systems in drug
562 delivery, *Drug Discov. Today*, 15 (2010) 1032-1040.
- 563 [17] H. Evenbratt, A. Strom, Phase behavior, rheology, and release from liquid crystalline
564 phases containing combinations of glycerol monooleate, glyceryl monooleyl ether,
565 propylene glycol, and water, *RSC Adv.*, 7 (2017) 32966-32973.
- 566 [18] L.B. Lopes, F.F. Speretta, M.V. Bentley, Enhancement of skin penetration of vitamin K
567 using monoolein-based liquid crystalline systems, *Eur. J. Pharm. Sci.*, 32 (2007) 209-215.
- 568 [19] I. Amar-Yuli, D. Libster, A. Aserin, N. Garti, Solubilization of food bioactives within
569 lyotropic liquid crystalline mesophases, *Curr. Opin. Colloid Interface Sci.*, 14 (2009) 21–32.
- 570 [20] F. Caboi, G.S. Amico, P. Pitzalis, M. Monduzzi, T. Nylander, K. Larsson, Addition of
571 hydrophilic and lipophilic compounds of biological relevance to the monoolein/water
572 system. Phase behaviour, *Chem. Phys. Lipids*, 109 (2001) 47-62.

- 573 [21] S.Z. Bathaie, R. Hoshyar, H. Miri, M. Sadeghizadeh, Anticancer effects of crocetin in
574 both human adenocarcinoma gastric cancer cells and rat model of gastric cancer.
575 *Biochem. Cell Biol.*, 91 (2013) 397-403.
- 576 [22] F. Yoshino, A. Yoshida, N. Umigai, K. Kubo, MC. Lee, Crocetin reduces the oxidative
577 stress induced reactive oxygen species in the stroke-prone spontaneously hypertensive
578 rats (SHRSPs) brain, *J. Clin. Biochem. Nutr.*, 49 (2011) 182-187.
- 579 [23] E. Christodoulou, N.P. Kadoglou, N. Kostomitsopoulos, G. Valsami, Saffron: A natural
580 product with potential pharmaceutical applications, *J. Pharm. Pharmacol.*, 67 (2015) 1634-
581 1649.
- 582 [24] M. Giaccio, Crocetin from saffron: an active component of an ancient spice, *Crit. Rev.*
583 *Food Sci. Nutr.*, 44 (2004) 155-172.
- 584 [25] L. Song, C. Kang, Y. Sun, W. Huang, W. Liu, Z. Qian, Crocetin Inhibits
585 Lipopolysaccharide- Induced Inflammatory Response in Human Umbilical Vein Endothelial
586 Cells, *Cell Physiol. Biochem.*, 40 (2016) 443-452.
- 587 [26] F. Bouvier, C. Suire, J. Mutterer, B. Camara, Oxidative remodeling of chromoplast
588 carotenoids: identification of the carotenoid dioxygenase CsCCD and CsZCD genes
589 involved in *Crocus* secondary metabolite biogenesis, *Plant Cell.*, 15 (2003) 47-62.
- 590 [27] O. Ahrazem, A. Rubio-Moraga, J. Berman, T. Capell, P. Christou, C. Zhu, L. Gómez-
591 Gómez, The carotenoid cleavage dioxygenase CCD2 catalysing the synthesis of crocetin
592 in spring crocuses and saffron is a plastidial enzyme, *New Phytol.*, 209 (2016) 650-663.
- 593 [28] T. Ohba, M. Ishisaka, S. Tsujii, K. Tsuruma, M. Shimazawa, K. Kubo, N. Umigai, T.
594 Iwawaki, H. Hara, Crocetin protects ultraviolet A-induced oxidative stress and cell death in
595 skin in vitro and in vivo, *Eur. J. Pharmacol.*, 789 (2016) 244-253.
- 596 [29] M. Tsimidou, E. Tsatsaroni, Stability of saffron pigments in aqueous extracts, *J. Food*
597 *Sci.*, 58 (1993) 1073-1075.

- 598 [30] P. D'Antona, W.O. Parker, M.C. Zanirato, E. Esposito, C. Nastruzzi, Rheological and
599 NMR characterization of monoglyceride-based formulations, *J. Biomed. Mater. Res.*, 52
600 (2000) 40-52.
- 601 [31] E. Esposito, V. Carotta, A. Scabbia, L. Trombelli, P. D'Antona, E. Menegatti, C.
602 Nastruzzi, Comparative analysis of tetracycline-containing dental gels: Poloxamer- and
603 monoglycerides-based formulations. *Int. J. Pharm.*, 142 (1996) 9-23.
- 604 [32] S. Mazzoni, L.R.S. Barbosa, S.S. Funari, R. Itri, P. Mariani, Cytochrome-c Affects the
605 Monoolein Polymorphism: Consequences for Stability and Loading Efficiency of Drug
606 Delivery Systems, *Langmuir*, 32 (2016) 873-881.
- 607 [33] A. Garg, D. Aggarwal, S. Garg, A.K. Singla, Spreading of semisolid formulations. An
608 update, *Pharm. Technol.*, 26 (2002) 84-105.
- 609 [34] W.J. Pugh, Kinetics of product stability. In: Aulton ME (Ed). *Aultons's Pharmaceutics.*
610 *The design and manufacture of the medicines*, 3rd ed. London: Churchill Livingstone
611 Elsevier (2007) pp:99-107
- 612 [35] M. Siewert, J. Dressman, C.K. Brown, V.P. Shah, FIP/AAPS guidelines to
613 dissolution/in vitro release testing of novel/special dosage forms, *AAPS PharmSciTech*, 4
614 (2003) E7.
- 615 [36] L.M. Andrade, C. de Fátima Reis, L. Maione-Silva, J.L.V. Anjos, A. Alonso, R.I.C.
616 Serpa, R.N. Marreto, E. M. Lima, S. F. Taveira, Impact of lipid dynamic behavior on
617 physical stability, in vitro release and skin permeation of genistein-loaded lipid
618 nanoparticles, *Eur. J. Pharm. Biopharm.*, s 88 (2014) 40–47
- 619 [37] E. Esposito, M. Sguizzato, M. Drechsler, P. Mariani, F. Carducci, C. Nastruzzi, R,
620 Cortesi, Progesterone lipid nanoparticles: Scaling up and in vivo human study, *Eur. J.*
621 *Pharm. Biopharm.*, 119 (2017) 437-446.
- 622 [38] M.-R. Van Calsteren, M. C. Bissonnette, F. Cormier, C. Dufresne, T. Ichi, J.C.Y.
623 LeBlanc, D. Perreault, I. Roewer, Spectroscopic characterization of crocetin derivatives

624 from *Crocus sativus* and *Gardenia jasminoides*, *J. Agric. Food Chem.*, 45 (1997) 1055-
625 1061.

626 [39] J. Briggs, H. Chung, M. Caffrey, The temperature-composition phase diagram and
627 mesophase structure characterization of the monoolein/water system, *J Phys II, EDP Sci.*,
628 6 (1996) 723-751.

629 [40] P. Mariani, V. Luzzati, H. Delacroix, Cubic phases of lipid-containing systems.
630 Structure analysis and biological implications, *J. Mol. Biol.*, 204 (1988) 165-189.

631 [41] C. C. Muller-Goymann, Physicochemical characterization of colloidal drug delivery
632 systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical
633 administration, *Eur. J. Pharm. Biopharm.*, 58 (2004) 343-356.

634 [42] Y. Iwashita, H. Tanaka, Self-organization in phase separation of a lyotropic liquid
635 crystal into cellular, network and droplet morphologies, *Nat. Mater.*, 5 (2006) 147-152.

636 [43] L. Sagalowicz, M. Michel, M. Adrian, P. Frossard, M. Rouvet, H.J. Watzke, A.
637 Yaghmur, L. de Campo, O. Glatter, M.E. Leser. Crystallography of dispersed liquid
638 crystalline phases studied by cryo-transmission electron microscopy, *J. Microsc.*, 221
639 (2006) 110-121.

640 [44] E. Esposito, M. Sguizzato, C. Bories, C. Nastruzzi, R. Cortesi, Production and
641 characterization of clotrimazole liposphere gel for candidiasis treatment, *Polymers*, 10
642 (2018) 160-175.

643 [45] E. Esposito, M. Drechsler, N. Huang, G. Pavoni, R. Cortesi, D. Santonocito, C. Puglia,
644 Ethosomes and organogels for cutaneous administration of crocin, *Biomed. Microdevices*,
645 18 (2016) 1-12.

646 [46] R. Mezzenga, C. Meyer, C. Servais, A.I. Romoscanu, L. Sagalowicz, R.C. Hayward,
647 Shear rheology of lyotropic liquid crystals: a case study, *Langmuir*, 21 (2005) 3322-3333.

648 [47] G. Bonacucina, G.F. Palmieri, D.Q.M. Craig, Rheological and dielectric
649 characterization of monoolein/water mesophases in the presence of a peptide drug, J.
650 Pharm. Sci., 94 (2005) 2452-2462.

651 [48] D.G. Lim, W.-W. Jeong, N.A. Kim, J.Y. Lim, S.-H. Lee, W.S. Shim, N.-G. Kang, S.H.
652 Jeong. Effect of the glyceryl monooleate-based lyotropic phases on skin permeation using
653 in vitro diffusion and skin imaging. Asian J. Pharm. Sci., 9 (2014) 324-329.

654 [49] N. Lars, A.-A. Ashraf, Stratum corneum keratin structure, function, and formation: the
655 cubic rod-packing and membrane templating model, J. Invest. Dermatol., 4 (2004) 715-
656 732.

657

658 **FIGURE LEGENDS**

659

660 **Figure 1.** SAXS profiles observed on monoolein, both in the absence (A) and in the
661 presence (B) of CRT 0.02% w/v, measured at 37°C. The black arrow indicates the
662 direction of the increasing concentration of water. Curves were separated using offset for
663 clarity.

664

665 **Figure 2.** Polarized light microscopy images of M-85-CRT (A), and M-90-CRT (B).
666 Observations were made using a magnification 10x.

667

668 **Figure 3.** Rheological flow curves of the indicated monoolein based formulations produced
669 in the absence (A) or in the presence (B) of CRT. Measurements were performed at 37°C.
670 The geometry used was an aluminium cone-plate. Flow curves were obtained by
671 increasing the shear rate from 0.01 s^{-1} to 5000 s^{-1} with 5 points per decade, each point
672 was maintained for a duration of 180 s to perform measurements in the permanent regime.
673 Data are the means of 3 analyses on different batches of the same type of formulations.

674

675 **Figure 4.** In vitro diffusion profiles of CUR from M-75-CRT (squares), M-90-CRT (circles)
676 and M-95-CRT (crosses). Experiments were performed by Franz cell associated to nylon
677 membranes. Data represent the mean of six independent experiments \pm S.D.

678

679 **Figure 5.** Tape stripping evaluation. A: CRT amount in the *stratum corneum* after M-90-
680 CRT, M-95-CRT and M-75-CRT application, removal and tape stripping. Tape stripping
681 was performed $t_{0.5}$ (white), t_3 (light) and t_6 (dark) from formulation removal. B: comparative

682 evaluation of the CRT level present at t_3 (light bars) and t_6 (dark bars) in *stratum corneum*.

683 The reported levels represent the percentage of CRT with respect to that present in

684 *stratum corneum* at $t_{0.5}$. Data represent the mean for ten subjects \pm S.D., $p < 0.001$.

685

686

687

688

689

1 Table 1: Composition of the studied monoolein based formulations

2

<i>Formulations</i>	<i>Monoolein (% w/w)</i>	<i>Water (% w/w)</i>	<i>Crocetin (% w/v)*</i>
M-75	75	25	-
M-80	80	20	-
M-85	85	15	-
M-90	90	10	-
M-95	95	5	-
M-75-CRT	75	25	0.02
M-80-CRT	80	20	0.02
M-85-CRT	85	15	0.02
M-90-CRT	90	10	0.02
M-95-CRT	95	5	0.02

3 *with respect to the volume of the formulations

4

5 Table 2. Macroscopic aspect, viscosity, phase symmetry and unit cell of monoolein
 6 based formulations measured at 37°C.

7

Formulations	Macroscopic aspect	Viscosity* (Pa.s) ± 5%	Phase symmetry^a	Unit cell^a (Å) ± 0.5
M-75	gel	1435	cubic Ia3d (Q230)	120.7
M-80	gel	3514	cubic Ia3d (Q230)	107.4
M-85	gel	3819	cubic Ia3d (Q230)	99.9
M-90	viscous	4.6	lamellar/micellar	37.6
M-95	liquid	0.3	micellar	34 (broad)
M-75-CRT	gel	1785	cubic Ia3d (Q230)	118.9
M-80-CRT	gel	3224	cubic Ia3d (Q230)	106.7
M-85-CRT	gel	3927	cubic Ia3d (Q230)	99.7
M-90-CRT	viscous	5.2	lamellar/micellar	37.4
M-95-CRT	liquid	0.3	micellar	34 (broad)

8 *shear rate 10⁵ s⁻¹; a: as determined by X-ray scattering. Monoolein based formulations acronyms
 9 are explained in Table 1.

10 Table 3. Shelf life data and CRT fluxes from the indicated monoolein based
 11 formulations
 12

Formulations	m^a	k^b	t_{90}^b(days)	$t_{1/2}^b$(days)	flux^c (cm/h*10³)
M-75-CRT	-0.0007	0.0017	58.67	389.32	2.37
M-90-CRT	-0.0016	0.0036	28.37	187.29	3.67
M-95-CRT	-0.0027	0.0063	16.51	109.1	4.37

13 a: slope of the line of log (CRT residual content %) kinetic, calculated as the mean of 3 independent
 14 determinations, s.d. \leq 2%; b: K, t_{90} and $t_{1/2}$ were calculated following equations. 2, 3 and 4
 15 respectively; c: calculated by Franz cell experiment, considering the slope of the line of CRT diffusion
 16 and its concentration in the monoolein formulations. Monoolein based formulations acronyms are
 17 explained in Table 1.
 18

Figure 1




Figure 1

Figure 2





Figure 2

Figure 3

A



B




Figure 3




Figure 4

Figure 5





Figure 5




Supplementary Material

[Click here to download Supplementary Material: Supplemental materials coll Surf B-R.docx](#)



Graphical Abstract




crocetin + monoolein/water



in vitro diffusion by Franz cell



Tape stripping



Highlights

- The natural antioxidant crocetin is very difficult to be solubilized in biocompatible vehicles
- Crocetin can be solubilized in monoolein/water systems leading to different mesophases
- Micellar, lamellar and Q230 phases have been found as a function of added water
- Viscosity and spreadability of monoolein systems allow crocetin application on skin
- Monoolein/water systems differently control crocetin diffusion through skin